The active development of TNK inhibitors is pursued for two reasons: first, Axin is the rate-limiting component of the β-catenin destruction complex[39]; second, Axin mutations and increased β-catenin levels are associated with various types of cancer[40]. Here, AXIN1 is linked to cancer.